Ashwagandha for Chronic Stress in Urban Men Awaits Trial Confirmation

On any given morning in Bengaluru, Mumbai, or Delhi, thousands of urban Indian men swallow a capsule of ashwagandha — often bought online or from a neighbourhood chemist — hoping to blunt the edge of work pressure, poor sleep, and irritability. The herb, formally Withania somnifera, has been a mainstay of Ayurveda for centuries. But the question of whether it actually works for chronic stress in the specific demographic that consumes it most — men aged 25 to 45 living in cities — remains largely unanswered by rigorous science.

Urban Men Swallow Ashwagandha Daily — But What Does the Evidence Say?

Sales of ashwagandha supplements in India's metropolitan areas have roughly doubled since 2020, according to market estimates cited by industry trackers. E-commerce platforms list hundreds of brands, many promising stress relief, better sleep, and even testosterone support. Yet the clinical trials that underpin these claims are far from definitive.

A 2021 meta-analysis published in the journal Cureus pooled data from five randomized controlled trials (RCTs) involving a total of about 400 participants. It found that ashwagandha root extract reduced cortisol levels by a modest but statistically significant amount — roughly 11 to 32 percent depending on the dose and duration. However, the authors noted that most studies were small, short (4 to 12 weeks), and included both men and women across a wide age range.

No trial has specifically enrolled urban Indian men with chronic stress as a primary population. The largest RCT to date, a 2020 study of 130 stressed adults, included only 52 men, and the authors did not report subgroup analyses by gender or urbanicity. This leaves a glaring gap between consumer behaviour and the evidence base.

Chronic Stress in Indian Men: A Neglected Epidemic

The World Health Organization has ranked India among countries with the highest prevalence of stress-related disorders, though exact prevalence data are hard to come by. The National Mental Health Survey of India, conducted in 2016, estimated that roughly 1 in 20 adult men suffer from a stress-related disorder such as generalized anxiety or adjustment disorder. Urban men report particular pressures: long commuting hours, job insecurity, sleep deprivation, and social expectations to be the primary earner.

Yet formal mental health care remains underused. A 2019 study in the Indian Journal of Psychiatry found that fewer than 10 percent of men with stress-related symptoms sought professional help. Instead, self-medication with adaptogens like ashwagandha, brahmi, and tulsi is common. A 2022 survey by the Indian Council of Medical Research noted that almost a third of urban men had tried an herbal supplement for stress in the previous year, with ashwagandha the most popular choice.

This pattern worries some clinicians. Dr. Priya Sharma, a psychiatrist at a private hospital in Bengaluru, told this reporter that she regularly sees men who have been taking ashwagandha for months without telling their doctor. "They assume it's natural, so it must be safe," she said. "But we don't know the long-term effects, especially on liver function or hormone levels, when taken unsupervised."

Ashwagandha's Mechanism: What Preclinical Data Shows

The biological plausibility of ashwagandha as a stress reliever rests on its effects on the hypothalamic-pituitary-adrenal (HPA) axis, the body's central stress response system. Animal studies, mostly in rats, show that extracts of the root can reduce corticosterone levels — the rodent analogue of cortisol — after exposure to physical or psychological stressors. In vitro work suggests that withanolides, the active compounds, may bind to GABA receptors, producing an anxiolytic effect similar to benzodiazepines but with a different safety profile.

Human pilot studies have reinforced these findings. A small 2012 study of 64 adults found that 300 mg of ashwagandha extract twice daily for 60 days led to a mean 26 percent reduction in serum cortisol compared with placebo. A 2019 trial of 60 healthy adults reported improvements in perceived stress scores and sleep quality after 8 weeks. But the doses used across studies vary from 125 mg to 1,250 mg per day, and the standardization of withanolide content is inconsistent. Some products contain as little as 1.5 percent withanolides, while others claim 5 percent or more. This makes it difficult to compare results or recommend a specific regimen.

"The preclinical data are intriguing, but they don't translate directly to a busy software engineer in Bangalore with chronic sleep debt," said Dr. Anil Kumar, a pharmacologist at the All India Institute of Medical Sciences in New Delhi, who was not involved in the studies. "We need human trials that mimic real-world conditions."

The Trial Gap: Why Urban Men Are Missing from Research

A search of the Clinical Trials Registry – India (CTRI) as of late 2024 reveals 12 registered trials of ashwagandha for stress or anxiety. Their average sample size is 60 participants. None specifically targets urban men. Most include both genders and a wide age range, from 18 to 65 years. The trials are also geographically dispersed, with sites in Pune, Kolkata, and Chennai, but none focus on high-stress urban occupational groups such as IT professionals, cab drivers, or sales executives.

This gap matters because stress manifests differently across demographics. Urban men may have distinct patterns of HPA-axis dysregulation — for instance, a blunted cortisol awakening response linked to chronic overwork — that a general population study might miss. Moreover, men are less likely than women to report subjective stress, so outcome measures like the Perceived Stress Scale (PSS-10) may need validation in this subgroup.

Dr. Meena Iyer, a researcher at the National Institute of Mental Health and Neurosciences in Bengaluru, pointed out that funding for herbal supplement trials in India is limited. "Pharma companies prefer to invest in synthetic drugs with patent potential," she said. "AYUSH [Ayurveda, Yoga, Unani, Siddha, and Homeopathy] products are not patentable in the same way, so large-scale trials are rare."

What a Proper Trial Would Need to Prove

To close the evidence gap, a definitive trial would need several design features. First, a primary endpoint that captures both subjective and objective stress. The PSS-10 is a validated tool, but it would need to be supplemented with salivary cortisol measured at multiple time points — ideally, at waking, 30 minutes after waking, and bedtime — to capture the diurnal rhythm. Secondary endpoints should include sleep quality (via the Pittsburgh Sleep Quality Index), testosterone levels, and a measure of work performance or absenteeism.

Sample size calculations based on the 2021 meta-analysis suggest that at least 300 participants would be needed to detect a moderate effect size with 80 percent power. The intervention should last at least 12 weeks, with follow-up at 24 weeks to assess durability. A control arm should receive either a placebo or a standardized stress management program — such as brief cognitive-behavioural therapy — to provide a meaningful comparator.

Subgroup analyses by age, baseline stress level, work hours, and urban versus peri-urban residence would help identify who benefits most. And the ashwagandha product itself must be standardized: a single batch with confirmed withanolide content, certified by an independent laboratory. Without such rigor, the results will remain as ambiguous as the current literature.

Regulatory Hurdles: AYUSH, FDA, and the Evidence Bar

The regulatory landscape for herbal supplements in India is complex. The Ministry of AYUSH promotes ashwagandha through its national programs and lists it in the Ayurvedic Pharmacopoeia. But unlike pharmaceutical drugs, herbal products do not require pre-market approval for safety or efficacy. The Drugs and Cosmetics Act, 1940, treats them as "drugs" only if they make therapeutic claims; many supplements sidestep this by using phrases like "supports stress management" rather than "treats stress."

In the United States, the Food and Drug Administration (FDA) has issued warning letters to several ashwagandha brands for marketing unapproved drug claims. The European Medicines Agency classifies ashwagandha as a "traditional use" herbal product, meaning it can be sold without proof of efficacy as long as it has been used for 30 years — including 15 in the EU. This lower bar means that a product can be legally sold even in the absence of robust trial data.

India's own pharmacopoeia does not include a monograph for ashwagandha for stress indication, only for general health. The result is a market where consumers rely on brand reputation and online reviews rather than clinical evidence. "We need a system where a supplement can carry a claim only if it has been proven in a trial that matches the population it is sold to," said Dr. Kumar. "That would be a game-changer — but it's not how the industry works right now."

The Cost-Benefit Trade-Off: Is Ashwagandha Worth Taking Without Proof?

Given the lack of definitive evidence, urban men face a real dilemma: should they take ashwagandha now, or wait for better trials? The answer depends on weighing potential benefits against risks and costs. On the benefit side, ashwagandha is generally well-tolerated in short-term studies. Common side effects are mild — drowsiness, upset stomach, or headache — and serious adverse events are rare. A 2020 systematic review of 69 studies found no significant difference in dropout rates between ashwagandha and placebo, suggesting acceptable tolerability.

However, the cost of ashwagandha supplements can add up. A month's supply of a reputable brand costs between ₹500 and ₹1,500 in India, depending on dosage and quality. For a man on a tight budget, that money might be better spent on a gym membership or a few sessions with a therapist — interventions with stronger evidence for stress reduction. Moreover, relying on a supplement might delay seeking effective treatment for an underlying condition like clinical depression or anxiety disorder, which requires professional care.

There is also the risk of interaction with other medications. Ashwagandha can lower blood sugar and blood pressure, so men on diabetes or hypertension drugs should use caution. It may also enhance the effects of sedatives or thyroid hormones. A 2023 case report in the Journal of Clinical and Diagnostic Research described a 34-year-old man who developed mild liver injury after taking high-dose ashwagandha for three months; while rare, such cases underscore the need for medical supervision.

Dr. Sharma advises her patients to think of ashwagandha as one tool among many. "If you have mild stress, good sleep hygiene, and no other health issues, trying ashwagandha under a doctor's guidance is reasonable," she says. "But if your stress is severe or you have other symptoms like chest pain or panic attacks, you need a full evaluation."

What Urban Men Can Do While Trials Are Pending

Until definitive evidence emerges, men considering ashwagandha for chronic stress should take several precautions. First, consult a physician or a qualified Ayurvedic practitioner before starting any supplement, especially if they have pre-existing conditions such as thyroid disorders, liver disease, or are on medications like sedatives or antihypertensives. Second, choose a product that specifies the withanolide content — typically 2.5 to 5 percent — and is certified by a third-party lab like the Indian Pharmacopoeia Commission or an international body such as USP.

Third, track symptoms systematically. A simple diary noting daily stress levels on a 1–10 scale, sleep hours, and any side effects can help both the user and their doctor assess whether the supplement is having any effect. Fourth, combine ashwagandha with evidence-based stress management techniques: regular aerobic exercise, sleep hygiene (consistent bedtimes, no screens before sleep), and mindfulness meditation, which has stronger trial support for stress reduction.

Finally, consider participating in a clinical trial. The CTRI lists several ongoing studies of ashwagandha for stress; enrolling helps build the evidence base. "Every person who joins a trial brings us closer to an answer," said Dr. Iyer. "We need urban men to be part of the solution, not just consumers of an unproven product."

The gap between what urban men take and what science knows about ashwagandha is wide. Bridging it will require not just larger trials, but a cultural shift in how we value evidence for traditional remedies. Until then, the best advice may be to treat ashwagandha as a supplement — not a substitute — for the harder work of managing stress through lifestyle change.